國立高雄大學圖資館 |

Language: English

Back

Real-world evidence in medical product development

Record Type:	Electronic resources : Monograph/item
Title/Author:	Real-world evidence in medical product developmentedited by Weili He, Yixin Fang, Hongwei Wang.
other author:	He, Weili.
Published:	Cham :Springer International Publishing :2023.
Description:	1 online resource (xxvii, 417 p.) :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
Subject:	Drug development.
Online resource:	https://doi.org/10.1007/978-3-031-26328-6
ISBN:	9783031263286$q(electronic bk.)

Real-world evidence in medical product development
Real-world evidence in medical product development[electronic resource] /edited by Weili He, Yixin Fang, Hongwei Wang. - Cham :Springer International Publishing :2023. - 1 online resource (xxvii, 417 p.) :ill., digital ;24 cm.

Preface -- Part I. Real-World Data and Evidence to Accelerate Medical Product Development -- The need for real world data/evidence in clinical development and life cycle management, and future directions -- Overview of current RWE/RWD landscape -- Key considerations in forming research questions -- Part II. Fit-for-use RWD Assessment and Data Standards -- Assessment of fit-for-use real-world data sources and applications -- Key variables ascertainment and validation in real-world setting -- Data standards and platform interoperability -- Privacy-preserving data linkage for real-world datasets -- Part III. Causal Inference Framework and Methodologies in RWE Research -- Causal Inference with Targeted Learning for Producing and Evaluating Real-World Evidence -- Framework and Examples of Estimands in Real-World Studies -- Clinical Studies Leveraging Real-World Data Using Propensity Score-Based Methods -- Recent statistical development for comparative effectiveness research beyond propensity-score methods -- Innovative Hybrid Designs and Analytical Approaches leveraging Real-Word Data and Clinical Trial data -- Statistical challenges for causal inference using time-to-event real-world data -- Sensitivity Analyses for Unmeasured Confounding: This is the way -- Sensitivity analysis in the analysis of real-world data -- Personalized medicine with advanced analytics -- Use of Real-World Evidence in Health Technology Assessment Submissions -- Part IV. Application and Case studies -- Examples of applying causal-inference roadmap to real-world studies -- Applications using real-world evidence to accelerate medical product development -- The use of real-world data to support the assessment of the benefit and risk of a medicine to treat spinal muscular atrophy -- Index.

This book provides state-of-art statistical methodologies, practical considerations from regulators and sponsors, logistics, and real use cases for practitioners for the uptake of RWE/D. Randomized clinical trials have been the gold standard for the evaluation of efficacy and safety of medical products. However, the cost, duration, practicality, and limited generalizability have incentivized many to look for alternative ways to optimize drug development. This book provides a comprehensive list of topics together to include all aspects with the uptake of RWE/D, including, but not limited to, applications in regulatory and non-regulatory settings, causal inference methodologies, organization and infrastructure considerations, logistic challenges, and practical use cases.

ISBN: 9783031263286$q(electronic bk.)

Standard No.: 10.1007/978-3-031-26328-6doiSubjects--Topical Terms:

190608
Drug development.

LC Class. No.: RM301.25

Dewey Class. No.: 615.19

Real-world evidence in medical product development
LDR:03584nmm a2200325 a 4500 001 638053
003 DE-He213
005 20230511182238.0
006 m d
007 cr nn 008maaau
008 230921s2023 sz s 0 eng d
020 $a 9783031263286$q(electronic bk.)
020 $a 9783031263279$q(paper)
024 7 $a 10.1007/978-3-031-26328-6 $2 doi
035 $a 978-3-031-26328-6
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.25
072 7 $a PBT $2 bicssc
072 7 $a MAT029000 $2 bisacsh
072 7 $a PBT $2 thema
082 0 4 $a 615.19 $2 23
090 $a RM301.25 $b .R288 2023
245 0 0 $a Real-world evidence in medical product development $h [electronic resource] / $c edited by Weili He, Yixin Fang, Hongwei Wang.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2023.
300 $a 1 online resource (xxvii, 417 p.) : $b ill., digital ; $c 24 cm.
505 0 $a Preface -- Part I. Real-World Data and Evidence to Accelerate Medical Product Development -- The need for real world data/evidence in clinical development and life cycle management, and future directions -- Overview of current RWE/RWD landscape -- Key considerations in forming research questions -- Part II. Fit-for-use RWD Assessment and Data Standards -- Assessment of fit-for-use real-world data sources and applications -- Key variables ascertainment and validation in real-world setting -- Data standards and platform interoperability -- Privacy-preserving data linkage for real-world datasets -- Part III. Causal Inference Framework and Methodologies in RWE Research -- Causal Inference with Targeted Learning for Producing and Evaluating Real-World Evidence -- Framework and Examples of Estimands in Real-World Studies -- Clinical Studies Leveraging Real-World Data Using Propensity Score-Based Methods -- Recent statistical development for comparative effectiveness research beyond propensity-score methods -- Innovative Hybrid Designs and Analytical Approaches leveraging Real-Word Data and Clinical Trial data -- Statistical challenges for causal inference using time-to-event real-world data -- Sensitivity Analyses for Unmeasured Confounding: This is the way -- Sensitivity analysis in the analysis of real-world data -- Personalized medicine with advanced analytics -- Use of Real-World Evidence in Health Technology Assessment Submissions -- Part IV. Application and Case studies -- Examples of applying causal-inference roadmap to real-world studies -- Applications using real-world evidence to accelerate medical product development -- The use of real-world data to support the assessment of the benefit and risk of a medicine to treat spinal muscular atrophy -- Index.
520 $a This book provides state-of-art statistical methodologies, practical considerations from regulators and sponsors, logistics, and real use cases for practitioners for the uptake of RWE/D. Randomized clinical trials have been the gold standard for the evaluation of efficacy and safety of medical products. However, the cost, duration, practicality, and limited generalizability have incentivized many to look for alternative ways to optimize drug development. This book provides a comprehensive list of topics together to include all aspects with the uptake of RWE/D, including, but not limited to, applications in regulatory and non-regulatory settings, causal inference methodologies, organization and infrastructure considerations, logistic challenges, and practical use cases.
650 0 $a Drug development. $3 190608
650 0 $a Clinical trials. $3 181901
650 1 4 $a Statistics. $3 182057
650 2 4 $a Data Science. $3 913495
650 2 4 $a Mathematics of Computing. $3 273710
700 1 $a He, Weili. $3 701737
700 1 $a Fang, Yixin. $3 944651
700 1 $a Wang, Hongwei. $3 348489
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-031-26328-6
950 $a Mathematics and Statistics (SpringerNature-11649)